Table 1.
Items | 10x Genomics | BD Rhapsody |
---|---|---|
Library Costs | $ 1600 | $ 1400 |
Time Costs | ~8 hours | ~10 hours |
Reproducibility | Pretty good | good |
Cell viability demand | >80% | >50% |
Cells loading | 500-25000 | 2000-40000 |
Cells recovery | 100-16000 | 100-25000 |
Safe stop points | 5 | 4 |
Single cell isolation | Microfluidics | Nanowells |
Cell Surface Protein | yes | yes |
Single Cell VDJ | yes | yes |
Single Cell ATAC | yes | no |
RNA capture beads | Gel beads | Magnetic beads |
Second strand cDNA synthesis | TSO | RPE |
Full-length cDNA | yes | no |
Advantage | High throughput Easy operation High cell recovery |
Monitor cells viability with imaging system Fewer doublets |
Limitations | Fresh samples needed Detect only 10% mRNA |
Fresh samples needed More hands work More cells input One sample per assay |
(median: over 1000), while 10x 3’ V3 ranges from 1000 to nearly 4000 per cell (median: around 2000) with each cell capturing around 2500 RNA molecules or 5000, respectively. The median mitochondrial genes percentile for BD methods is a little bit more than 10x, while 10x delivers the range of mitochondrial genes percentile from 5 to 15. This result indicates that due to different capture mechanisms, the BD system could tolerate less cell viability, while 10x scRNASeq clearly delivers a better RNA capture rate. Therefore, the BD system might be better for a less accessible patient sample. As for cell type capture capability, there is not much difference as indicated in Fig. (4). Both methods could capture lymphocytes, myeloid cells and granulocytes well.